Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Sheryl Krevsky Elkin"'
Publikováno v:
Clinical lung cancer. 21(6)
Two recent studies examining the clinical and economic value of next-generation sequencing (NGS)-based diagnostic testing (multi-gene panel examining ≥ 30 genes) for non–small-cell lung cancer therapy compared with single gene ALK, EGFR testing t
Publikováno v:
Cancer Biology & Therapy
Cancer biology & therapy, vol 20, iss 2
Cancer biology & therapy, vol 20, iss 2
Despite being one of the most common cancers, treatment options for prostate cancer are limited. Novel approaches for advanced disease are needed. We evaluated the relative rate of use of clinical-grade next generation sequencing (NGS) in prostate ca
Autor:
Razelle Kurzrock, Shumei Kato, Vivek Subbiah, Erica Marchlik, Jennifer L. Carter, Sheryl Krevsky Elkin
Publikováno v:
Clinical Cancer Research. 23:1988-1997
Purpose: Aberrations in genetic sequences encoding the tyrosine kinase receptor RET lead to oncogenic signaling that is targetable with anti-RET multikinase inhibitors. Understanding the comprehensive genomic landscape of RET aberrations across multi
Autor:
Dan Barnett, Jamie Randall, Sarah Mullaly, Gail Payne, Erica Marchlik, Sheryl Krevsky Elkin, Danny Rayes, Hongkun Wang, Raymond C. Wadlow, Lindsey Tishman, Timothy L. Cannon
Publikováno v:
Journal of Clinical Oncology. 39:129-129
129 Background: KRAS and NRAS (RAS) mutations are considered driver mutations in gastrointestinal malignancies such as colorectal and pancreatic cancer. Our institution obtains broad molecular testing (commercial panels with full exon coverage of at
Autor:
Jennifer L. Carter, Razelle Kurzrock, Shumei Kato, Timon P.H. Buys, Brett N. Tomson, Sheryl Krevsky Elkin
Publikováno v:
Molecular Cancer Therapeutics. 15:2498-2507
Understanding the genomic landscape of malignant mesothelioma may identify novel molecular drivers of this ultra-rare disease, which can lead to an expanded roster of targeted therapies and clinical trial options for patients with mesothelioma. We ex
Autor:
Brett N. Tomson, Jennifer L. Carter, Timon P.H. Buys, Maria Schwaederle, Sheryl Krevsky Elkin, Shumei Kato, Teresa Helsten, Razelle Kurzrock
Publikováno v:
Molecular Cancer Therapeutics. 15:1682-1690
Alterations in the cyclin-dependent kinase (CDK)-retinoblastoma (RB) machinery disrupt cell-cycle regulation and are being targeted in drug development. To understand the cancer types impacted by this pathway, we analyzed frequency of abnormalities i
Publikováno v:
Personalized medicine. 8(3)
N-of-One is at the forefront of personalized medicine. The company’s mission is to act as a bridge between the research community, diagnostic laboratories, the treating oncologist and the patient to develop customized cancer diagnostic and treatmen
Autor:
Geoffrey R. Oxnard, Jennifer L. Carter, E. Kelly Sullivan, Russell W. Jenkins, David A. Barbie, Sheryl Krevsky Elkin
Publikováno v:
Clinical Lung Cancer. 16:e101-e104
MET (c-MET; mesenchymal-epithelial transition factor) is a receptor tyrosine kinase that was first characterized as a proto-oncogene in 1984, in a chemically transformed osteosarcoma cell line [1]. Located on chromosome 7q21-31, the MET gene encodes
Autor:
Erica Marchlik, Sheryl Krevsky Elkin, Razelle Kurzrock, Brett N. Tomson, Jennifer L. Carter, Philip R. Cohen
Publikováno v:
Cohen, PR; Tomson, BN; Elkin, SK; Marchlik, E; Carter, JL; & Kurzrock, R. (2016). Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics. ONCOTARGET, 7(17), 23454-23467. doi: 10.18632/oncotarget.8032. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/3xn6s72f
Oncotarget
Oncotarget, vol 7, iss 17
Oncotarget
Oncotarget, vol 7, iss 17
Merkel cell carcinoma is an ultra-rare cutaneous neuroendocrine cancer for which approved treatment options are lacking. To better understand potential actionability, the genomic landscape of Merkel cell cancers was assessed. The molecular aberration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bcd1d62748764b0331cf58672d693d5
http://www.escholarship.org/uc/item/3xn6s72f
http://www.escholarship.org/uc/item/3xn6s72f
Autor:
John M. Jessup, Anam Asif, Sheryl Krevsky Elkin, Jennifer L. Carter, Timothy L. Cannon, Laura Knopp, Donald L. Trump, Jo-Ellen Murphy
Publikováno v:
Journal of Clinical Oncology. 36:483-483
483 Background: Inova Schar Cancer Institute formed a molecular tumor board in early 2016 to identify treatment options for patients with gastrointestinal malignances based on molecular testing and to track outcomes. Methods: From March 2016 to June